Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 57, Issue 11, Pages 1589-1597Publisher
SPRINGER
DOI: 10.1007/s00262-008-0489-2
Keywords
immunotherapy; dendritic cells; maturation; cell trafficking; tumor immunology; Toll-like receptor ligands
Categories
Funding
- Dutch Cancer Society [KUN 2003/2917, 2004/3126, 2004/3127, 2006/3699]
- ZonMW [917.76.363]
- EU projects Cancer Immunotherapy
- DC-THERA
Ask authors/readers for more resources
Dendritic cells (DC) are professional antigen-presenting cells of the immune system that play a key role in regulating T cell-based immunity. In vivo, the capacity of DC to activate T cells depends on their ability to migrate to the T cell areas of lymph nodes as well as on their maturation state. Depending on their cytokine-secreting profile, DC are able to skew the immune response in a specific direction. In particular, IL-12p70 producing DC drive T cells towards a T helper 1 type response. A serious disadvantage of current clinical grade ex vivo generated monocyte-derived DC is the poor IL-12p70 production. We have investigated the effects of Toll-like receptor (TLR)-mediated maturation on ex vivo generated human monocyte-derived DC. We demonstrate that in contrast to cytokine-matured DC, DC matured with poly(I:C) (TLR3 ligand) and/or R848 (TLR7/8 ligand) are able to produce vast amounts of IL-12p70, but exhibit a reduced migratory capacity. The addition of prostaglandin E(2) (PGE(2)) improved the migratory capacity of TLR-ligand matured DC while maintaining their IL-12p70 production upon T cell encounter. We propose a novel clinical grade maturation protocol in which TLR ligands poly(I:C) and R848 are combined with PGE(2) to generate DC with both high migratory capacity and IL-12p70 production upon T cell encounter.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available